Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29
Scott Andrew Laurie, Benjamin Solomon, Lesley Seymour et al. · European Journal of Cancer · 2013
Cited by 101 works. doi:10.1016/j.ejca.2013.11.032
Authors
- Scott Andrew Laurie
- Benjamin Solomon
- Lesley Seymour
- Glenwood D. Goss
- Frances A. Shepherd
- Michael Joseph Boyer
- Andrew Arnold
- Philip R. Clingan
- Francis Laberge
- David William Fenton
- Vera Hirsh
- Mauro Zukin
- Martin R. Stockler
- C.W. Lee
- E X Chen
- Alexander Montenegro
- Keyue Ding
- Penelope A. Bradbury
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial
- What Is the Evidence That Tumors Are Angiogenesis Dependent?
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
- Critical review of the international assessments of health-related quality of life
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
- Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
- Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors